Cerebellar ataxia associated with anti-glutamic acid decarboxylase (anti-GAD) autoantibodies: a rare and puzzling disease

Hélio A. G. Teive

Neurological disorders associated with anti-glutamic acid decarboxylase autoantibodies (anti-GAD Abs) include stiff-person syndrome (SPS) and its variants (stiff-trunk syndrome, stiff-limb syndrome, progressive encephalomyelitis with rigidity and myoclonus [PERM], or “SPS plus”, and paraneoplastic SPS) as well as epilepsy, abnormal eye movements, limbic encephalitis and cerebellar ataxia1,2. These syndromes are often found in association with other autoimmune disorders, such as type 1 diabetes mellitus, Addison’s disease, thyroiditis, vitiligo, hemolytic anemia, myasthenia gravis, vitamin B12 deficiency due to autoimmune destruction of parietal cells (pernicious anemia) and polyglandular autoimmune syndromes1,2,3,4. GAD is a cytoplasmic enzyme that produces GABA (γ-aminobutyric acid), the main inhibitory neurotransmitter in the central nervous system (CNS). It is expressed predominantly in CNS GABAergic neurons and pancreatic islet β-cells and has two isoforms, GAD 65, which is more involved in neurological diseases, and GAD 671,2,3,4. GAD is also found in the liver, kidneys, adrenal glands, ovaries and testes, but in lower concentrations. Anti-GAD Abs inhibit GAD activity and synthesis of GABA1,2,3,4. Anti-GAD 65 autoantibodies were described initially in type 1 diabetes mellitus patients and are considered a biomarker for this disease3. In 1956, Moersch and Woltman5 published a case report of a 49-year-old man with progressive fluctuating muscular rigidity and spasm (“stiff-man syndrome”) along with observations of thirteen other cases. More recently, the term “stiff-man syndrome” was replaced by “stiff-person syndrome” (SPS), and anti-GAD autoantibodies were found to be associated with this disorder and its variants4. Immune-mediated cerebellar ataxias include gluten ataxia, paraneoplastic cerebellar degeneration, ataxia associated with systemic lupus erythematosus, Hashimoto’s encephalopathy (cerebellar type), primary autoimmune cerebellar ataxia and cerebellar ataxia associated with GAD autoantibodies (GAD Abs-CA)4. This last condition was described in 1997 by Saiz et al.6 in three patients who also had late-onset insulin-dependent diabetes mellitus and polyendocrine autoimmunity. Since then, several case reports and a study of a small series of patients have been published7,8, as well as a study of fourteen patients by Honnorat et al.9 published in 2001. GAD Abs-CA occurs most commonly in women in their sixth decade, and the prognosis is usually poor4,10. In 2008, Hadjivassiliou et al.11 published a prospective study on the prevalence of immune-mediated cerebellar ataxia. Of 400 patients with progressive cerebellar ataxia, 23 % had idiopathic sporadic ataxia. The prevalence of autoimmune disease in this group was 47%. Gluten ataxia was diagnosed in 27% of the patients, paraneoplastic cerebellar degeneration (PCD) in 3% and GAD Abs-CA in 2%.11 In this issue of Arquivos de Neuro-Psiquiatria, Aguiar et al.12 describe the clinical characteristics of patients with GAD Abs-CA. In their retrospective study they evaluate three patients with this condition (one female and two males, mean age 49.3 years), two of whom also had SPS. All the patients had high GAD-Ab titers (> 100 IU/mL) without any paraneoplastic neurological syndromes. After treatment with intravenous immunoglobulin, one patient made a partial recovery but the two others showed no improvement.12 Associated endocrine disease included latent autoimmune diabetes in adults (LADA) in two patients, and autoimmune polyglandular endocrinopathy type 2, or Schmidt’s syndrome in one patient12. In 2016, Mitoma et al.13 published a review of guidelines for treatment of immune-mediated cerebellar ataxias. They concluded that although various types of immunotherapies (including intravenous methylprednisolone, intravenous immunoglobulins, plasma exchange and rituximab)
have been used in patients with GAD Abs-CA, most patients continue to have significant disability and a poor prognosis.\(^\text{10}\) However, in clinical practice some patients with this disorder show an improvement in the cerebellar ataxia symptoms\(^\text{2A,9}\).

Despite the controversy surrounding treatment of this condition and its prognosis, it is now imperative that neurologists be able to recognize this form of auto-immune cerebellar ataxia caused by anti-GAD Abs.

References


